COMMUNIQUÉS West-GlobeNewswire

JSC Olainfarm Informs About Registration Of New Collateral
17/06/2019
To finance its daily activities and investments Olainfarm Group in the past attracted loan facilities from SEB and ABLV banks. Such information is disclosed in financial statements. This year existing credit agreements [...]
Kevin Harris elected Ducks Unlimited Canada’s 44th president
17/06/2019
New Brunswick conservationist to lead country’s premier wetland conservation organization OAK HAMMOCK MARSH, Man., June 17, 2019 (GLOBE NEWSWIRE) -- Ducks Unlimited Canada (DUC) has elected Kevin Harris as its 44 th [...]
Kevin Harris élu 44e président de Canards Illimités Canada
17/06/2019
Ce conservationniste du Nouveau-Brunswick dirigera le plus prestigieux organisme de conservation des milieux humides du pays marais Oak Hammock (Manitoba), 17 juin 2019 (GLOBE NEWSWIRE) -- Canards Illimités Canada (CIC [...]
Aclaris Therapeutics Announces Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical in Patients with Androgenetic Alopecia (Male/Female Pattern-Baldness)
17/06/2019
WAYNE, Pa., June 17, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced positive [...]
Calithera Achieves Positive Topline Results in Randomized Phase 2 ENTRATA Study of Telaglenastat with Everolimus in Renal Cell Carcinoma
17/06/2019
-Doubled median progression-free survival (PFS) in heavily pre-treated patients with advanced renal cell carcinoma -Provides first clinical proof of concept for glutaminase inhibitor telaglenastat -Management to host [...]
VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®
17/06/2019
Both co-primary endpoints successfully met – including non-inferiority in all adults age ≥18 years, and superiority in adults age ≥ 45 years Seroprotection rates four weeks post-3 rd vaccination of Sci-B-Vac® vs. [...]
Arrayit Corporation Reports Clinical Laboratory Certificate of Deemed Status by the State of California Department of Public Health
17/06/2019
Sunnyvale, June 17, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC ), a life sciences and personalized medicine company, in accordance with the provisions of the Business and Professions Code has received [...]
Share buy-back week 24/2019
17/06/2019
Announcement 17 June 2019 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 2/2019 Coloplast has initiated the second part of the share buy-back programme totalling up [...]
BBS announces a share issue of approximately 12.7-16.8 MSEK to expand the owner base in Sweden
17/06/2019
The Board of Directors of BBS – Bioactive Bone Substitutes Oyj (“BBS” or “Company”), an innovator in orthobiologics, has today decided to conduct a share issue based on the authorization granted at the Annual General [...]
Terveystalo's occupational health services to expand: Terveystalo acquires the occupational health operations from Welfare District of Forssa
17/06/2019
Press Release 17 June 2019 Terveystalo will buy the occupational health operations of Welfare District of Forssa by an agreement signed on 17 June 2019. Terveystalo will also become the occupational health care provider [...]
NeuroSearch announces a change to its financial outlook for 2019
17/06/2019
Company announcement 17 June 2019 In its Annual Report 2018, NeuroSearch announced an expected operating loss (on a going-concern assumption) of approximately DKK 4-6 million. The expectations did not include expenses [...]
VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®
16/06/2019
CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, will [...]
Strategy update for the three-year period 2020-2022
16/06/2019
Read the full announcement in PDF Attachment 2019_18_Strategy 2020-2022_20190616 EN
Apellis Pharmaceuticals
16/06/2019
CRESTWOOD, Ky. and WALTHAM Mass., 16 juin 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), une société biopharmaceutique de stade clinique axée sur le développement de nouveaux composés [...]
ROADSTER-2 Demonstrates Compelling Patient Outcomes with Strong Safety Profile
15/06/2019
Final Results Presented in Late-Breaking Session at Society for Vascular Surgery 2019 Vascular Annual Meeting NATIONAL HARBOR, Md., June 15, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company [...]
Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting
15/06/2019
SOUTH SAN FRANCISCO, Calif., June 15, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent [...]
Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
15/06/2019
IND-enabling activities initiated for EDIT-301, a potentially best-in-class experimental medicine for the treatment of sickle cell disease and beta-thalassemia CAMBRIDGE, Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Editas [...]
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress
15/06/2019
CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
15/06/2019
-- 5F9 Well-Tolerated in Combination with Rituximab -- -- Durable Responses Observed in DLBCL and Indolent Lymphoma; Median Duration of Response Not Yet Reached -- -- Overall Response Rate (ORR) of 36% Observed in DLBCL [...]

Pages